ClinicalTrials.gg
TerminatedNCT00979576Updated Mar 6, 2025Results posted

BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)

A Phase 1 interventional study of BIBF 1120 M + Pemetrexed and BIBF 1120 H + Pemetrexed in Carcinoma, Non-Small-Cell Lung, sponsored by Boehringer Ingelheim. Terminated at 3 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2025-03-06.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 2 under way, none of them phase 3. nintedanib · Carcinoma, Non-Small-Cell Lung.

Enrollment
9th of 19
19 · median 16
Started
2009
the only one that year
Phase 1
9 of 19
none open now
Registered
3rd of 19
by date
Lead sponsor
10 of 19
Boehringer Ingelheim

Among the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by enrollment, is the only one that started in 2009, is one of 9 in phase 1, and was the 3rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The objectives of this trial are to estimate the following in Japanese patients with advanced NSCLC of stage IIIB/IV or with recurrence after failure of first-line chemotherapy.

Phase I part The objective of the phase I part is to define the Maximum Tolerated Dose (MTD) of BIBF 1120 at a dose level up to twice daily 200 mg with standard dose of pemetrexed (500 mg/m\^2) and to determine the Recommended Dose (RD) for the phase II part.

Phase II, to investigate the efficacy and safety of BIBF 1120 in combination with pemetrexed (500 mg/m\^2) as compared to pemetrexed (500 mg/m\^2) + placebo

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients of age >=20 and \<=74 years at
  2. or cytologically confirmed, Non Small Cell Lung Cancer (NSCLC) of stage IIIB or IV or recurrent NSCLC
  3. Relapse or failure of 1 prior chemotherapy
  4. of at least 3 months
  5. (ECOG) score of 0 or 1
  6. Patients who have sufficient baseline organ function over 4 weeks and whose laboratory data meet the following criteria at the enrolment

    • >=9.0 g/dL
    • (ANC) >=1500/mm\^3
    • count >=100 000/mm\^3
    • Total under the
    • /SGOT and/or ALT/GPT \<=1.5 x upper limit of normal (if related to liver \<=2.5 x upper limit of normal also)
    • Proteinuria (CTCAE) grade 1 or less
    • Calculated by Cockcroft Gault >=45 mL/min
    • -international normalized ratio (PT-INR) and/or partial thromboplastin time (PTT) greater than 50% deviation from normal limits
    • arterial oxgen pressure (PaO2) >=60 torr or oxygen saturation by pulse-oximeter SpO2 >=92%
  7. Patient has given written informed consent which must be consistent with ICH-GCP and local legislation.

Exclusion criteria

Exclusion criteria:

  1. Patients who have received treatment with other drugs or treatment in another clinical trial within the past 4 weeks before start of therapy or concomitantly with this trial or who have not recovered from side effects of such therapy (except for alopecia)
  2. Patients who have received chemo-, hormone-, immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks prior to treatment with the trial drug or who have not recovered from side effects of such therapy (except for alopecia) .
  3. Patients who have received radiotherapy within the following period Phase I part: the past 4 weeks prior to treatment with the trial drug (in case of palliative radiotherapy such as for extremities, within the past 2 weeks prior to treatment with the trial drug)
  4. Previous therapy with other vascular endothelial growth factor receptor (VEGFR) inhibitors or vascular endothelial growth factor (VEGF) ligand inhibitors for treatment of NSCLC
  5. Previous therapy with BIBF 1120 and/or pemetrexed for treatment of NSCLC and any for therapy with pemetrexed
  6. Patients who have active
  7. Patients with distinct or suspected pulmonary fibrosis or interstitial lung disease by the CT findings, or patients with a previous history of pulmonary fibrosis or interstitial lung disease (except irradiation-pneumonitis appearing radiation field with past radiotherapy).
  8. Radiographic evidence of cavitary or necrotic tumors
  9. Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of major blood vessels
  10. History of haemoptysis within the past 3 months
  11. History of major thrombotic or clinically relevant major bleeding event in the past 6 months
  12. Known inherited predisposition to bleeding or thrombosis
  13. Significant cardiovascular diseases
  14. Significant weight loss (>10%) within the past 6 weeks prior to treatment in the present trial
  15. Current peripheral neuropathy grade 2 or greater except due to trauma
  16. Pre-existing ascites and/or clinically significant pleural effusion
  17. Major injuries and/or surgery within the past 4 weeks prior to randomisation with incomplete wound healing
  18. Clinically serious infections
  19. Decompensated diabetes mellitus
  20. Contraindication to high dose therapy
  21. Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
  22. Patients who have active or chronic and/or B infection and diagnosis of (HIV) infection
  23. Other other than basal cell skin cancer, carcinoma in situ or intra-mucosal cancer that were judged to be cured by adequate treatment and disease-free interval is more than 5 years
  24. History of serious drug
  25. Serious illness or concomitant non-oncological disease such as neurologic-, psychiatric-, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation
  26. Therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy
  27. Patients who are sexually active and unwilling to use a medically acceptable method of
  28. Pregnancy or breast feeding
  29. Active alcohol or drug abuse
  30. Patients unable to comply with the protocol
  31. Other patients judged ineligible for enrolment in the study by the investigator or subinvestigator.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
19 participants (actual)

Study arms

  • Experimental
    BIBF 1120 BID + Pemetrexed

    Phase I part: Find MTD by using low, medium or high BIBF 1120 twice daily and 500mg/m\^2 pemetrexed once every 3 weeks

    Drug: BIBF 1120 M + Pemetrexed · Drug: BIBF 1120 H + Pemetrexed · Drug: BIBF 1120 L + Pemetrexed

  • Experimental
    BIBF 1120 BID (RD) + Pemetrexed

    PHase II part: Study arm

    Drug: BIBF 1120 RD + Pemetrexed

  • Experimental
    BIBF 1120 BID(Placebo) + Pemetrexed

    Phase II part: Comparator arm

    Drug: BIBF 1120 Placebo + Pemetrexed

Interventions

  • DrugBIBF 1120 M + Pemetrexed

    Drug pages: Nintedanib · Pemetrexed

    BIBF 1120 medium dose bid+ Pemetrexed 500 mg/m\^2

  • DrugBIBF 1120 H + Pemetrexed

    Drug pages: Nintedanib · Pemetrexed

    BIBF 1120 high dose bid+ Pemetrexed 500 mg/m\^2

  • DrugBIBF 1120 RD + Pemetrexed

    Drug pages: Nintedanib · Pemetrexed

    confirmed dose of BIBF 1120 bid + Pemetrexed 500 mg/m\^2

  • DrugBIBF 1120 L + Pemetrexed

    Drug pages: Nintedanib · Pemetrexed

    BIBF 1120 low dose bid+ Pemetrexed 500 mg/m\^2

  • DrugBIBF 1120 Placebo + Pemetrexed

    placebo BIBF 1120 bid + Pemetrexed 500 mg/m\^2

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities

    Number of participants with dose limiting toxicity (DLT) in combination therapy of BIBF 1120 and pemetrexed during the first course

    Time frame: During the first course, 21 days

  2. Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 for All Courses

    Number of patients with adverse events according to worst Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 for all courses. CTCAE grades are: 1 (mild AE), 2 (moderate AE), 3 (severe AE), 4 (life-threatening or disabling AE) or 5 (death related to AE).

    Time frame: Between first administration of pemetrexed and 28 days after last administration of pemetrexed and/or BIBF 1120, up to 1020 days

Secondary outcomes

  1. Overall Response Rate

    Number of participants with complete response (CR) or partial response (PR) according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.0

    Time frame: Every 6 weeks after start of study treatment until end of treatment, up to 992 days

  2. Disease Control Rate

    Number of participants with complete response (CR), partial response (PR) or stable disease (SD) according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.0

    Time frame: Every 6 weeks after start of study treatment until end of treatment, up to 992 days

  3. Duration of Disease Control

    Duration of disease control was defined as the time period from the first study drug administration to the progressive disease (PD) or death of patients, whichever occurred earlier.

    Time frame: From first study drug administration until PD or death, up to 1003 days

  4. Number of Participants With Clinically Relevant Abnormalities in Laboratory Parameters

    Number of participants with clinically relevant abnormalities in laboratory parameters reported as adverse events which occurred in \>= 20% of patients

    Time frame: Between first administration of pemetrexed and 28 days after last administration of pemetrexed and/or BIBF 1120, up to 1020 days

  5. AUC0-inf of Nintedanib

    Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)

    Time frame: 5 minutes (min) before nintedanib administration and 1h, 2h, 3h, 4h, 6h, 7h, 10h and 23h 55min after nintedanib administration in cycle 1

  6. Cmax of Nintedanib

    Maximum measured concentration of nintedanib in plasma (Cmax)

    Time frame: 5 minutes (min) before nintedanib administration and 1h, 2h, 3h, 4h, 6h, 7h, 10h and 23h 55min after nintedanib administration in cycle 1

  7. AUC0-inf of Pemetrexed

    Area under the concentration-time curve of pemetrexed in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)

    Time frame: 5 minutes (min) before pemetrexed administration and 10min, 40min, 1 hour (h), 2h, 4h, 6h, 23h 55min, 47h 55min after pemetrexed administration in cycles 1 and 2

  8. Cmax of Pemetrexed

    Maximum measured concentration of pemetrexed in plasma (Cmax)

    Time frame: 5 minutes (min) before pemetrexed administration and 10min, 40min, 1 hour (h), 2h, 4h, 6h, 23h 55min, 47h 55min after pemetrexed administration in cycles 1 and 2

07

Results

Posted Nov 20, 2014
Limitations and caveats
The trial was planned to comprise of two parts, with the phase II being based on the results of another study. The other study was stopped early due to futility analysis therefore only phase I of the study was completed.

Participant flow

Combination Treatment Phase
Participant flow — Combination Treatment Phase
MilestoneBIBF 1120 100 mg + Pemetrexed 500 mg/m^2BIBF 1120 150 mg + Pemetrexed 500 mg/m^2BIBF 1120 200 mg + Pemetrexed 500 mg/m^2
Started369
Completed000
Not completed369
Withdrew: Progressive disease315
Withdrew: Dose limiting toxicity032
Withdrew: Adverse event022
Combination Followed by Monotherapy
Participant flow — Combination Followed by Monotherapy
MilestoneBIBF 1120 100 mg + Pemetrexed 500 mg/m^2BIBF 1120 150 mg + Pemetrexed 500 mg/m^2BIBF 1120 200 mg + Pemetrexed 500 mg/m^2
Started021
Completed000
Not completed021
Withdrew: Progressive disease021

Outcome measures

PrimaryDose Limiting Toxicities

Number of participants with dose limiting toxicity (DLT) in combination therapy of BIBF 1120 and pemetrexed during the first course

Time frame:
During the first course, 21 days
Reported as:
Number · Participants
Dose Limiting Toxicities
ParticipantsBIBF 1120 100 mg + Pemetrexed 500 mg/m^2BIBF 1120 150 mg + Pemetrexed 500 mg/m^2BIBF 1120 200 mg + Pemetrexed 500 mg/m^2
Dose Limiting Toxicities012
PrimaryAdverse Events According to Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 for All Courses

Number of patients with adverse events according to worst Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 for all courses. CTCAE grades are: 1 (mild AE), 2 (moderate AE), 3 (severe AE), 4 (life-threatening or disabling AE) or 5 (death related to AE).

Time frame:
Between first administration of pemetrexed and 28 days after last administration of pemetrexed and/or BIBF 1120, up to 1020 days
Reported as:
Number · participants
Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 for All Courses
participantsBIBF 1120 100 mg + Pemetrexed 500 mg/m^2BIBF 1120 150 mg + Pemetrexed 500 mg/m^2BIBF 1120 200 mg + Pemetrexed 500 mg/m^2
Grade 1001
Grade 2212
Grade 3155
Grade 4001
Grade 5000
SecondaryOverall Response Rate

Number of participants with complete response (CR) or partial response (PR) according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.0

Time frame:
Every 6 weeks after start of study treatment until end of treatment, up to 992 days
Reported as:
Number · Participants
Overall Response Rate
ParticipantsBIBF 1120 100 mg + Pemetrexed 500 mg/m^2BIBF 1120 150 mg + Pemetrexed 500 mg/m^2BIBF 1120 200 mg + Pemetrexed 500 mg/m^2
Complete response000
Partial response011
SecondaryDisease Control Rate

Number of participants with complete response (CR), partial response (PR) or stable disease (SD) according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.0

Time frame:
Every 6 weeks after start of study treatment until end of treatment, up to 992 days
Reported as:
Number · Participants
Disease Control Rate
ParticipantsBIBF 1120 100 mg + Pemetrexed 500 mg/m^2BIBF 1120 150 mg + Pemetrexed 500 mg/m^2BIBF 1120 200 mg + Pemetrexed 500 mg/m^2
Disease Control Rate246
SecondaryDuration of Disease Control

Duration of disease control was defined as the time period from the first study drug administration to the progressive disease (PD) or death of patients, whichever occurred earlier.

Time frame:
From first study drug administration until PD or death, up to 1003 days
Reported as:
Median · Days
Duration of Disease Control
DaysBIBF 1120 100 mg + Pemetrexed 500 mg/m^2BIBF 1120 150 mg + Pemetrexed 500 mg/m^2BIBF 1120 200 mg + Pemetrexed 500 mg/m^2
Duration of Disease Control248.5 (162 to 335)228.5 (168 to 587)149.0 (121 to 1003)
SecondaryNumber of Participants With Clinically Relevant Abnormalities in Laboratory Parameters

Number of participants with clinically relevant abnormalities in laboratory parameters reported as adverse events which occurred in \>= 20% of patients

Time frame:
Between first administration of pemetrexed and 28 days after last administration of pemetrexed and/or BIBF 1120, up to 1020 days
Reported as:
Number · participants
Number of Participants With Clinically Relevant Abnormalities in Laboratory Parameters
participantsBIBF 1120 100 mg + Pemetrexed 500 mg/m^2BIBF 1120 150 mg + Pemetrexed 500 mg/m^2BIBF 1120 200 mg + Pemetrexed 500 mg/m^2
Alanine aminotransferase increased268
Gamma-glutamyltransferase increased258
Aspartate aminotransferase increased257
Lymphocyte count decreased212
Neutrophil count decreased234
White blood cell count decreased223
Blood alkaline phosphatase increased014
Blood albumin decreased013
Haemoglobin decreased113
SecondaryAUC0-inf of Nintedanib

Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)

Time frame:
5 minutes (min) before nintedanib administration and 1h, 2h, 3h, 4h, 6h, 7h, 10h and 23h 55min after nintedanib administration in cycle 1
Reported as:
Geometric mean · ng*h/mL
AUC0-inf of Nintedanib
ng*h/mLBIBF 1120 100 mg + Pemetrexed 500 mg/m^2BIBF 1120 150 mg + Pemetrexed 500 mg/m^2BIBF 1120 200 mg + Pemetrexed 500 mg/m^2
AUC0-inf of Nintedanib105 ± 25.5232 ± 60.5323 ± 28.8
SecondaryCmax of Nintedanib

Maximum measured concentration of nintedanib in plasma (Cmax)

Time frame:
5 minutes (min) before nintedanib administration and 1h, 2h, 3h, 4h, 6h, 7h, 10h and 23h 55min after nintedanib administration in cycle 1
Reported as:
Geometric mean · ng/mL
Cmax of Nintedanib
ng/mLBIBF 1120 100 mg + Pemetrexed 500 mg/m^2BIBF 1120 150 mg + Pemetrexed 500 mg/m^2BIBF 1120 200 mg + Pemetrexed 500 mg/m^2
Cmax of Nintedanib20.5 ± 31.037.9 ± 71.755.1 ± 29.6
SecondaryAUC0-inf of Pemetrexed

Area under the concentration-time curve of pemetrexed in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)

Time frame:
5 minutes (min) before pemetrexed administration and 10min, 40min, 1 hour (h), 2h, 4h, 6h, 23h 55min, 47h 55min after pemetrexed administration in cycles 1 and 2
Reported as:
Geometric mean · ng*h/mL
AUC0-inf of Pemetrexed
ng*h/mLPemetrexed 500 mg/m2
Cycle 1194000 ± 19.9
Cycle 2 (N=11)200000 ± 15.9
SecondaryCmax of Pemetrexed

Maximum measured concentration of pemetrexed in plasma (Cmax)

Time frame:
5 minutes (min) before pemetrexed administration and 10min, 40min, 1 hour (h), 2h, 4h, 6h, 23h 55min, 47h 55min after pemetrexed administration in cycles 1 and 2
Reported as:
Geometric mean · ng/mL
Cmax of Pemetrexed
ng/mLPemetrexed 500 mg/m2
Cycle 1139000 ± 16.5
Cycle 2 (N=11)149000 ± 15.4

Adverse events

Collected over Between first administration of pemetrexed and 28 days after last administration of pemetrexed and/or BIBF 1120, up to 1020 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BIBF 1120 100 mg + Pemetrexed 500 mg/m^2—1/3 (33.3%)3/3 (100%)
BIBF 1120 150 mg + Pemetrexed 500 mg/m^2—0/6 (0%)6/6 (100%)
BIBF 1120 200 mg + Pemetrexed 500 mg/m^2—1/9 (11.1%)9/9 (100%)
Most frequent serious events
Most frequent serious events
EventBIBF 1120 100 mg + Pemetrexed 500 mg/m^2BIBF 1120 150 mg + Pemetrexed 500 mg/m^2BIBF 1120 200 mg + Pemetrexed 500 mg/m^2
FatigueGeneral disorders1/30/60/9
HypercalcaemiaMetabolism and nutrition disorders1/30/60/9
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/30/61/9
Most frequent other events
Showing 10 of 95
Most frequent other events
EventBIBF 1120 100 mg + Pemetrexed 500 mg/m^2BIBF 1120 150 mg + Pemetrexed 500 mg/m^2BIBF 1120 200 mg + Pemetrexed 500 mg/m^2
Alanine aminotransferase increasedInvestigations2/36/68/9
Gamma-glutamyltransferase increasedInvestigations2/35/68/9
DiarrhoeaGastrointestinal disorders2/35/67/9
Aspartate aminotransferase increasedInvestigations2/35/67/9
RashSkin and subcutaneous tissue disorders1/35/63/9
ConstipationGastrointestinal disorders2/31/61/9
NauseaGastrointestinal disorders2/33/64/9
StomatitisGastrointestinal disorders2/32/61/9
VomitingGastrointestinal disorders2/31/64/9
FatigueGeneral disorders2/34/61/9

Baseline characteristics

Treated set: all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment

Age, Continuous
Age, Continuous(years)BIBF 1120 100 mg + Pemetrexed 500 mg/m^2BIBF 1120 150 mg + Pemetrexed 500 mg/m^2BIBF 1120 200 mg + Pemetrexed 500 mg/m^2Total
Median61.0 (60 to 66)66.0 (54 to 70)64.0 (30 to 70)64.0 (30 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)BIBF 1120 100 mg + Pemetrexed 500 mg/m^2BIBF 1120 150 mg + Pemetrexed 500 mg/m^2BIBF 1120 200 mg + Pemetrexed 500 mg/m^2Total
Female1214
Male24814
08

Study locations

3 sites
  • 1199.28.003 Boehringer Ingelheim Investigational Site
    Chiba,Kashiwa, Japan
  • 1199.28.002 Boehringer Ingelheim Investigational Site
    Miyakojima-ku, Osaka, Japan
  • 1199.28.001 Boehringer Ingelheim Investigational Site
    Osaka-Sayama, Osaka, Japan
09

References and documents

Publications

  • Daga H, Takeda K, Okada H, Miyazaki M, Ueda S, Kaneda H, Okamoto I, Yoh K, Goto K, Konishi K, Sarashina A, Tanaka T, Kaiser R, Nakagawa K. Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2015 Dec;76(6):1225-33. doi: 10.1007/s00280-015-2896-3. Epub 2015 Nov 11. PubMed 26560486 ↗

Related links

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2009 to primary completion in Feb 2015, 64 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2009
First posted
Sep 18, 2009
StartActual
Oct 16, 2009
Primary completionActual
Feb 16, 2015
CompletionActual
Feb 16, 2015
Results first posted
Nov 20, 2014
Last update
Mar 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00979576
Responsible party
Sponsor
First posted
Sep 18, 2009
Start date
Oct 16, 2009
Primary completion
Feb 16, 2015
Completion
Feb 16, 2015
Results posted
Nov 20, 2014
Last update
Mar 6, 2025

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nintedanib · Pemetrexed

Start the discussion